Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 13, 2024

SELL
$38.75 - $51.0 $2,518 - $3,315
-65 Closed
0 $0
Q1 2021

Aug 13, 2024

SELL
$26.34 - $83.07 $1,712 - $5,399
-65 Reduced 50.0%
65 $3.33 Million
Q4 2020

Aug 13, 2024

BUY
$25.51 - $43.38 $3,316 - $5,639
130 New
130 $3.48 Million

Others Institutions Holding VIR

About Vir Biotechnology, Inc.


  • Ticker VIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 132,638,000
  • Market Cap $1.31B
  • Description
  • Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...
More about VIR
Track This Portfolio

Track Glen Eagle Advisors, LLC Portfolio

Follow Glen Eagle Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Glen Eagle Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Glen Eagle Advisors, LLC with notifications on news.